One of the biggest tailwinds in the pharmaceutical industry is weight loss treatments. Breakthroughs in semaglutide and tirzepatide have given rise to several glucagon-like peptide-1 (GLP-1) medications, including Ozempic, Rybelsus, Wegovy, Mounjaro, and Zepbound.

While that is a long list of treatments, only two companies are the brains behind these blockbuster drugs: Novo Nordisk and Eli Lilly.

Recently, a smaller company called Viking Therapeutics made waves in the weight loss scene following a successful phase 2 trial for its obesity candidate VK273.

Continue reading

Source Fool.com